Iyo New Drug Submission yeCCIDID (NDS-CV) maitiro akabvumira kuendeswa kwezvikamu zvisiri zvekiriniki, mhando, kuchengetedzwa kwekiriniki, uye ruzivo rwekuita sezvavakavepo kuti Health Canada iongororwe nekukasira kuti ikurumidze kuita ongororo yese. Kuendesa iyo Phase 3 data kunopedzisa maitiro ekutumira.
Iyo yekudzora mafaera emumiriri weCCIDID-19 yakatangwa neFDA (US) uye MHRA (UK). Hurukuro yekutanga iri kuenderera mberi neWHO yekugadzirira kutumira. Chiyedzo cheChikamu 1/2 chakatangwa zvakare muJapan uko Medicago inoronga kuendesa kuti ibvumidzwe nemutemo pamwe chete neChikamu 2/3 chezvidzidzo zvepasi rose chirimo chinotevera. Mumiriri wejekiseni haasati atenderwa nevakuru vehutano.
"Kana ikabvumidzwa, mushonga weMedicago weCCIDID-19 ungave wepasi rose wekudzivirira wekudyara wakabvumidzwa kushandiswa nevanhu," akadaro Takashi Nagao, CEO uye Mutungamiriri weMedicago. "Ingave zvakare yekudzivirira yekuCanada yekutanga kubvumidzwa mumakore anopfuura makumi maviri, zvichiratidza danho rine simba rekugadzirira chirongwa cheCanada chekugadzirira."
ZVOKUBVA MUNYAYA INO:
- Chiyedzo cheChikamu 1/2 chakatangwa zvakare muJapan uko Medicago inoronga kuendesa kuti ibvumidzwe nemutemo pamwe chete neChikamu 2/3 chezvidzidzo zvepasi rose muchirimo chinotevera.
- Iyo New Drug Submission yeCCIDID (NDS-CV) maitiro akabvumira kuendeswa kwezvikamu zvisiri zvekiriniki, mhando, kuchengetedzwa kwekiriniki, uye ruzivo rwekuita sezvavakavepo kuti Health Canada iongororwe nekukurumidza kuti ikurumidze kuita ongororo yese.
- "Ingave zvakare yekudzivirira yekudzivirira yekuCanada yekutanga kubvumidzwa mumakore anopfuura makumi maviri, zvichiratidza danho rine simba rekugadzirira chirongwa cheCanada chekugadzirira.
